1365694-06-9

Upstream product

• 1365694-18-3 C₁₃H₂₆O₂Si 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 78906-15-7 tert-butyldimethylsilyl (S)-glycidyl ether 

Downstream Products

• 1365694-07-0 (S)-2-(t-butyldiphenylsilyloxy)hept-4-yn-1-ol 
• 1365694-08-1 (2S,4Z)-2-(t-butyldiphenylsilyloxy)hept-4-en-1-ol 
• 1365694-09-2 (2S,4Z)-2-(tert-butyldiphenylsilyloxy)hept-4-enal 
• 1365694-04-7 C₂₄H₃₀OSi 
• 916888-47-6 resolvin D3 

Relevant academic research and scientific papers

COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES

This invention provides compounds, methods and compositions for the treatment of inflammatory diseases, comprising the timely administration of a provided compound, which has a structure related to an endogenously formed lipid mediator. One embodiment of the present invention is directed to a compound selected from a group having the general formula A.

Stereocontrolled total synthesis of the potent anti-inflammatory and pro-resolving lipid mediator resolvin D3 and its aspirin-triggered 17 R-epimer

The first total synthesis of stereochemically pure resolvin D3 and aspirin-triggered resolvin D3 is reported. These enzymatic metabolites of docosahexaenoic acid (DHA) have potent anti-inflammatory and pro-resolving actions. The convergent synthetic strategy is based on enantiomerically pure starting materials, and it is highly stereocontrolled.

Stereocontrolled total synthesis of Neuroprotectin D1/Protectin D1 and its aspirin-triggered stereoisomer

Neuroprotectin D1/Protectin D1, a potent anti-inflammatory, proresolving, and neuroprotective lipid mediator derived biosynthetically from docosahexaenoic acid, was prepared in an enantiomerically pure form via total organic synthesis. The synthetic strategy is highly stereocontrolled and convergent, featuring epoxide opening of glycidol starting materials for the introduction of the 10(R) and 17(S) hydroxyl groups. The desired alkene Z geometry was secured via the cis-reduction of alkyne precursors, while the conjugated E,E,Z triene was introduced at the end, in order to minimize Z/E isomerization. The same strategy, was also employed for the total synthesis of aspirin-triggered neuroprotectin D1/protectin D1 having the 17(R)-stereochemistry. Synthetic compounds obtained with the reported method were matched with endogenously derived materials, and helped establish their complete stereochemistry.